Anatara Lifesciences Ltd (ASX:ANR)

Market Cap	2.53M -27.0%
Revenue (ttm)	318.40K -67.2%
Net Income	-933.23K
EPS	-0.00
Shares Out	315.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	560,300
Open	0.0080
Previous Close	0.0080
Day's Range	0.0080 - 0.0080
52-Week Range	0.0080 - 0.0170
Beta	0.67
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About Anatara Lifesciences

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include irritable bowel syndrome; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral complementary medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ANR

Financial Performance

In fiscal year 2026, Anatara Lifesciences's revenue was 318,402, a decrease of -67.16% compared to the previous year's 969,456. Losses were -933,230, -52.26% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error